MedTrace Logo

Collection of Bone Marrow From Donors Treated With or Without Filgrastim

NCT01149096 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-02-26

Study results available
· View outcomes & findings →

Summary

This randomized clinical trial is studying the side effects of collection of bone marrow from donors treated with or without filgrastim. Giving colony-stimulating factors, such as filgrastim (G-CSF), to donors helps the stem cells move from the bone marrow to the blood so they can be collected and stored.

Conditions

  • Healthy Stem Cell Donor
  • No Evidence of Disease

Interventions

PROCEDURE

Bone Marrow Donation

Undergo bone marrow harvest

BIOLOGICAL

Filgrastim

Given subcutaneously

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Stephan A Grupp · Children's Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-14
Primary Completion
2011-12-14
Completion
2016-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01149096 on ClinicalTrials.gov